Pathological complete response in breast cancer patients following neoadjuvant chemotherapy at a Comprehensive Cancer Center: The natural history of an elusive prognosticator

Fayanju,Oluwadamilola  M.; Nwaogu,Iheoma; Jeffe,Donna  B.; Margenthaler,Julie  A.

doi:10.3892/mco.2015.535

Pathological complete response in breast cancer patients following neoadjuvant chemotherapy at a Comprehensive Cancer Center: The natural history of an elusive prognosticator

Authors:
- Oluwadamilola M. Fayanju
- Iheoma Nwaogu
- Donna B. Jeffe
- Julie A. Margenthaler
View Affiliations

Affiliations: Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA, Division of General Medical Sciences, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
Published online on: March 31, 2015 https://doi.org/10.3892/mco.2015.535
Pages: 775-780

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Given the prognostic significance of pathological complete response (pCR) to neoadjuvant chemotherapy, we sought to chronicle the clinical course of breast cancer patients whose tumors exhibited pCR at our institution. We retrospectively reviewed 5,533 cancer center patients treated for a first primary breast cancer between March, 1999 and September, 2010 to identify those who received neoadjuvant chemotherapy that resulted in pCR (i.e., no residual invasive malignancy in the breast or axilla). The descriptive statistics of treatments received, recurrence, morbidity and mortality as of October, 2013 were reported. Of the 5,533 patients reviewed, 86 met the inclusion criteria. The mean age at diagnosis was 48 years [standard deviation (SD), 9.4 years] and the mean length of follow‑up was 68 months (SD, 27 months). The majority of the patients underwent axillary lymph node dissection (ALND; n=60, 69.8%), received adjuvant radiation therapy (XRT; n=72, 83.7%), had poorly differentiated (grade 3) tumors (n=74, 86.1%) and had pure ductal histology (n=74, 86.1%). A total of 5 patients (5.8%) developed disease recurrence. All the patients who recurred had grade 3 tumors with ductal histology and underwent ALND for known pre‑neoadjuvant‑treatment lymph node metastases; none received adjuvant chemotherapy. A total of 4 patients (4.7%) succumbed to the disease, 3 due to breast cancer recurrence <18 months following the initial diagnosis. Recurrence following pCR was rare, but when it did occur, time‑ to‑recurrence was short at <18 months. All the patients who recurred and eventually succumbed to breast cancer had axillary metastases at diagnosis, indicating that axillary disease is a major negative prognostic factor in patients who achieve pCR following neoadjuvant chemotherapy.

View Figures

View References

1	Lee JK, Coutant C, Kim YC, Qi Y, Theodorescu D, Symmans WF, Baggerly K, Rouzier R and Pusztai L: Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 16:711–718. 2010. View Article : Google Scholar : PubMed/NCBI
2	Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA and Hortobagyi GN: Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 23:8331–8339. 2005. View Article : Google Scholar : PubMed/NCBI
3	Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A and Pusztai L: Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 19:1508–1516. 2012. View Article : Google Scholar : PubMed/NCBI
4	U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Guidance for Industry Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval. Retrieved from. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM305501.pdfApril 10–2014
5	Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P and Baselga J: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 375:377–384. 2010. View Article : Google Scholar : PubMed/NCBI
6	Hutcheon AW, Heys SD and Sarkar TK: Aberdeen Breast Group: Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat. 79:(Suppl 1). S19–S24. 2003. View Article : Google Scholar : PubMed/NCBI
7	Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F and Konecny GE: Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 27:2938–2945. 2009. View Article : Google Scholar : PubMed/NCBI
8	Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN and Singletary SE: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 17:460–469. 1999.PubMed/NCBI
9	Rouzier R, Extra J-M, Klijanienko J, Falcou MC, Asselain B, Vincent-Salomon A, Vielh P and Bourstyn E: Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol. 20:1304–1310. 2002. View Article : Google Scholar : PubMed/NCBI
10	Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van't Veer L and Hylton N: Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: Results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 30:3242–3249. 2012. View Article : Google Scholar : PubMed/NCBI
11	Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN and Pusztai L: Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 25:2650–2655. 2007. View Article : Google Scholar : PubMed/NCBI
12	von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K and Loibl S: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 30:1796–1804. 2012. View Article : Google Scholar : PubMed/NCBI
13	Montagna E, Bagnardi V, Rotmensz N, Viale G, Pruneri G, Veronesi P, Cancello G, Balduzzi A, Dellapasqua S, Cardillo A, Luini A, Zurrida S, Gentilini O, Mastropasqua MG, Bottiglieri L, Iorfida M, Goldhirsch A and Colleoni M: Pathological complete response after preoperative systemic therapy and outcome: Relevance of clinical and biologic baseline features. Breast Cancer Res Treat. 124:689–699. 2010. View Article : Google Scholar : PubMed/NCBI
14	von Minckwitz G, Kaufmann M, Kuemmel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Hilfrich J, Jackisch C, Gerber B, Du Bois A, Huober JB, Hanusch CA, Konecny GE, Fett W, Stickeler E, Harbeck N, Mehta K, Loibl S and Untch M: and GBG and AGO-B study groups: Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. J Clin Oncol. 29:10282011.
15	Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN and Meric-Bernstam F: Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 28:1821–1828. 2010. View Article : Google Scholar : PubMed/NCBI
16	Boughey JC, Peintinger F, Meric-Bernstam F, Perry AC, Hunt KK, Babiera GV, Singletary SE, Bedrosian I, Lucci A, Buzdar AU, Pusztai L and Kuerer HM: Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 244:464–470. 2006.PubMed/NCBI
17	van Nes JG, Putter H, Julien JP, Tubiana-Hulin M, van de Vijver M, Bogaerts J, de Vos M and van de Velde CJ: Cooperating Investigators of the EORTC: Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat. 115:101–113. 2009. View Article : Google Scholar : PubMed/NCBI
18	Zhang GC, Zhang YF, Xu FP, Qian XK, Guo ZB, Ren CY and Yao M: Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer. Curr Oncol. 20:e180–e192. 2013. View Article : Google Scholar : PubMed/NCBI
19	Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W and Dowsett M: Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 100:1380–1388. 2008. View Article : Google Scholar : PubMed/NCBI
20	Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU and Hortobagyi GN: Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol. 23:7098–7104. 2005. View Article : Google Scholar : PubMed/NCBI
21	Tanioka M, Shimizu C, Yonemori K, Yoshimura K, Tamura K, Kouno T, Ando M, Katsumata N, Tsuda H, Kinoshita T and Fujiwara Y: Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. Br J Cancer. 103:297–302. 2010. View Article : Google Scholar : PubMed/NCBI